Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Leica Bond Oracle HER2 IHC System (Product ...
Leica Biosystems, unveiled ChromoPlex III Triple Detection RUO, a chromogenic multiplex immunohistochemistry detection system engineered to simplify assay setup and reduce variability. ChromoPlex III ...
Leica Biosystems will develop a fully automated HER2 diagnostic to support identification of appropriate HER2 negative (IHC 1+/2+) patients for NeuVax™ (nelipepimut-S or E75) Galena strengthens its ...
Leica Biosystems announces the availability of the Novocastra™ HD menu for breast pathology, the first portfolio of independently qualified* antibodies from the new Novocastra HD range. Together with ...
Leica Biosystems announces the launch of the fourth Novocastra™ HD menu, focused on hematopathology. Previously launched were the Novocastra HD menus for breast, head & neck and dermatopathology. The ...
(MENAFN- PR Newswire) The BOND MMR Antibody Panel is now available for clinical use on BOND-III and BOND-MAX Immunohistochemistry (IHC) automated instruments. NEWCASTLE, United Kingdom, April 3, 2023 ...
Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the analysis of target protein expression in subsets of specific cells within the context of ...
Leica Biosystems, a leading provider of pathology products and solutions, globally launched a new PD-L1 antibody for use on their fully automated BOND IHC and ISH staining platform. The new PD-L1 ...
Leica Biosystems developed the Novocastra HD menu with the aim of producing a high performance range of antibodies for the most commonly performed IHC tests. Each antibody was evaluated by an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback